Should adjuvant CRT be considered in gastric cancer patients who received pre-op chemo based on the recent results of the CRITICS trial?

Topics: Radiation Oncology • Gastrointestinal Cancers

The CRITICS trial showed there was no OS or PFS benefit with adj chemo vs CRT. Is there potentially still a role for CRT to reduce heme toxicity and potentially improve LRC?

Answer from: Radiation Oncologist at Academic Institution

There are many nuances here, but CRITICS suggests that there is little if any benefit to the routine use of postoperative chemoRT, in addition to pre- and post-op chemo, in resected gastric cancer patients who undergo a D2 dissection. The only scenario where I really consider postop CRT to be strong...

Comments

Radiation Oncologist at University of Cincinnati College of Medicine
I agree with @Abraham J. Wu. Whether there is a ro...

Radiation Oncologist at Center for Neurosciences
Would you consider post-operative CRT in patients ...

Radiation Oncologist at Memorial Sloan Kettering Cancer Center
These are all great questions without clear-cut an...

Related Questions